Diabetes is life long affliction that causes a person’s blood sugar level to become too high. With the two main types of diabetes, type 2 is far more common. Around 90% of all adults with diabetes have type 2.
Types
Type 2 is where the body is not creating enough insulin or the body is not reacting correctly to the insulin. This type usually requires the managing of medication, finding the right medication for each person can take time. Also many of the medications have side affects.
Type 1 is when the level of glucose in blood to be too high. This happens when the body isn’t producing enough of the hormone insulin which controls the levels of glucose in blood.
Both types are manageable with the correct advice and medication.
There are articles below that explore the condition in many different ways. Covering new research and evidence.
Afon Technology is pioneering advancements in diabetes care with its innovative device, Glucowear™, which is being developed as the world’s first non-invasive, real-time, continuous blood glucose monitor.
Here, Mark Clements, MD PhD, paediatric endocrinologist, clinical investigator, and chief medical officer at Glooko Inc. takes part in a Q&A regarding his perspectives on remote clinical trials and data management tools.
Jane C Khoury & Shelley R Ehrlich from Division of Biostatistics and Epidemiology, Cincinnati Children’s Hospital Medical Center, highlight the consequences of foetal development in a “sweet” uterus – including the short- and long-term transgenerational outcomes.
Jean Van Rampelbergh PhD, VP Clinical & Regulatory at Imcyse SA, introduces ImotopesTM a cutting-edge immunotherapy science with an excellent safety profile that could cure Type 1 diabetes or drastically change treatment options.
Claus Møldrup, DrugsDisclosed.com Founder and Former Professor in Social Pharmacy at the University of Copenhagen, turns the spotlight on diabetes and explores how to improve patient wellbeing and national health outcomes.
While diabetes has been declared as a signifier for infection complications, researchers now say that data suggests it is three times as likely these individuals have severe COVID or are hospitalised.
Katerina Kousoulaki, Christos Tsatsanis, Tone-Kari K. Østbye and Francisco J. Barba of the AQUABIOPRO-FIT project discuss the health benefits of dietary products made from fish side streams.
Cecilia Van Cauwenberghe from Frost & Sullivan’s TechVision Group considers how the standard of healthcare for patients with diabetes is impacted by COVID-19.
Dr Lucy Chambers, Head of Research Communications at Diabetes UK, provides us with her thoughts on COVID-19 and diabetes, in terms of what do we (not) know.
Professor Sandra Carvalho, University of Minho, Department of Physics, discusses the emergence of surface functionalization as a strategy in biotech and health.
Jean Van Rampelbergh PhD, VP Clinical & Regulatory at Imcyse SA, introduces Imotopes™, the innovative new immunotherapy approach causing scientists to rethink Type 1 diabetes and its treatment.
Hjalte Hojsgaard, Insulet International, highlights why choice of insulin delivery devices is important, and why access to this life-changing technology is not yet fully utilised in UK diabetes services.
